174 related articles for article (PubMed ID: 10335496)
1. Antiglutamate therapies in Huntington's disease.
Kieburtz K
J Neural Transm Suppl; 1999; 55():97-102. PubMed ID: 10335496
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in Huntington's disease.
Gutekunst CA; Norflus F; Hersch SM
Curr Opin Neurol; 2000 Aug; 13(4):445-50. PubMed ID: 10970063
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model.
Schilling G; Coonfield ML; Ross CA; Borchelt DR
Neurosci Lett; 2001 Nov; 315(3):149-53. PubMed ID: 11716985
[TBL] [Abstract][Full Text] [Related]
5. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
Bates GP; Hockly E
Curr Opin Neurol; 2003 Aug; 16(4):465-70. PubMed ID: 12869804
[TBL] [Abstract][Full Text] [Related]
6. Huntington's disease: which drugs might help patients?
Hannan AJ
IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
[TBL] [Abstract][Full Text] [Related]
7. Bioenergetics in Huntington's disease.
Grünewald T; Beal MF
Ann N Y Acad Sci; 1999; 893():203-13. PubMed ID: 10672239
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease.
Huntington Study Group
Neurology; 2001 Aug; 57(3):397-404. PubMed ID: 11502903
[TBL] [Abstract][Full Text] [Related]
9. Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum.
Butterworth NJ; Williams L; Bullock JY; Love DR; Faull RL; Dragunow M
Neuroscience; 1998 Nov; 87(1):49-53. PubMed ID: 9722140
[TBL] [Abstract][Full Text] [Related]
10. [Importance of the number of trinucleotide repeat expansions in the clinical manifestations of Huntington's chorea].
Vojvodić N; Culjković B; Romac S; Stojković O; Sternić N; Sokić D; Kostić VS
Srp Arh Celok Lek; 1998; 126(3-4):77-82. PubMed ID: 9863360
[TBL] [Abstract][Full Text] [Related]
11. Weight loss in Huntington disease increases with higher CAG repeat number.
Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
[TBL] [Abstract][Full Text] [Related]
12. Etiology of (CAG)n triplet repeat neurodegenerative diseases such as Huntington's disease is connected to stimulation of glutamate receptors.
Fischer KM
Med Hypotheses; 1997 May; 48(5):393-8. PubMed ID: 9185124
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of G-protein coupled receptors in Huntington's disease.
Dowie MJ; Scotter EL; Molinari E; Glass M
Pharmacol Ther; 2010 Nov; 128(2):305-23. PubMed ID: 20708032
[TBL] [Abstract][Full Text] [Related]
14. [Molecular genetics of Huntington's disease].
Goto J; Masuda N; Watanabe M; Kanazawa I
Rinsho Shinkeigaku; 1995 Dec; 35(12):1529-31. PubMed ID: 8752453
[TBL] [Abstract][Full Text] [Related]
15. [Huntington's disease].
Rollnik JD
Nervenarzt; 2015 Jun; 86(6):725-35. PubMed ID: 25940443
[TBL] [Abstract][Full Text] [Related]
16. Advances in Huntington's disease: implications for experimental therapeutics.
Feigin A
Curr Opin Neurol; 1998 Aug; 11(4):357-62. PubMed ID: 9725082
[TBL] [Abstract][Full Text] [Related]
17. Prospects for neuroprotective therapies in prodromal Huntington's disease.
Chandra A; Johri A; Beal MF
Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
[TBL] [Abstract][Full Text] [Related]
18. Huntington's disease as caused by 34 CAG repeats.
Andrich J; Arning L; Wieczorek S; Kraus PH; Gold R; Saft C
Mov Disord; 2008 Apr; 23(6):879-81. PubMed ID: 18307262
[TBL] [Abstract][Full Text] [Related]
19. George Huntington (1850-1916) and hereditary chorea.
Lanska DJ
J Hist Neurosci; 2000 Apr; 9(1):76-89. PubMed ID: 11232352
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of remacemide hydrochloride in Huntington's disease.
Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
